DPP-IV Isoform Diagnosis via Free-Flow Electrophoresis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing diseases, such as type 2 diabetes, are invasive, time-consuming, and limited in providing accurate prognosis, relying on subjective factors and cumbersome testing like fasting plasma glucose tests.
Innovation Solution
The method involves measuring parameters of discriminated dipeptidyl peptidase (DPP) isoforms from patient samples using free-flow electrophoresis to correlate with the presence, absence, or severity of disease states, specifically focusing on DPP-IV isoforms for type 2 diabetes diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fasting plasma glucose test is used for diagnosis, then diagnosis of type 2 diabetes is achieved, but the process is time-consuming and requires multiple blood draws over hours to days
Solution Approach 1:
The patent replaces the mechanical blood drawing process with a minimally invasive blood spot collection method. Instead of requiring multiple venous blood draws over hours, the system uses capillary blood spots collected from the finger tip, which can be obtained quickly and repeatedly without significant patient discomfort or time loss.
Solution Approach 2:
The patent changes the diagnostic parameter from fasting plasma glucose concentration to DPP-IV enzyme activity measured in blood spots. This parameter change enables diagnosis within minutes rather than requiring hours of fasting and multiple blood draws, as the enzyme activity can be directly measured in the blood spot samples.
2Reliability
If fasting plasma glucose test is used for diagnosis, then presence of type 2 diabetes is detected, but the test is very limited in its ability to provide disease prognosis
Solution Approach 1:
The patent segments the DPP-IV enzyme into different isoforms (DPP-IVa and DPP-IVb) through electrophoretic separation. By analyzing the ratio and activity of these specific isoforms, the system provides detailed prognostic information about disease severity and progression, going beyond what simple plasma glucose levels can indicate.
Solution Approach 2:
The patent uses DPP-IV enzyme activity as an intermediary marker that bridges the gap between diagnosis and prognosis. The enzyme activity levels and isoform distribution serve as a mediator that not only indicates the presence of diabetes but also correlates with disease severity, treatment response, and long-term outcomes, providing comprehensive prognostic information.
3Reliability
If invasive surgery or biopsies are used for diagnosis, then definitive diagnosis is obtained, but the process is physically taxing and cumbersome
Solution Approach 1:
The patent replaces invasive surgical procedures and biopsies with a non-invasive blood spot analysis method. Instead of requiring tissue sampling from internal organs or deep tissues, the system measures DPP-IV enzyme activity in easily obtainable capillary blood spots, eliminating the physical trauma and discomfort associated with invasive procedures while maintaining diagnostic accuracy.
Solution Approach 2:
The patent uses blood spots as an intermediary medium that contains the DPP-IV enzyme. This intermediary approach allows definitive diagnosis without directly sampling affected tissues, as the enzyme in the blood spots serves as a proxy marker that reflects the disease state with the same diagnostic reliability as invasive biopsies but without the physical harm.
4Measurement precision
If multiple blood draws over hours to days are performed, then accurate diagnosis is achieved, but the process becomes cumbersome and physically taxing
Solution Approach 1:
The patent changes the measurement parameter from repeated plasma glucose concentrations to single-point DPP-IV enzyme activity measurement in blood spots. This parameter change maintains diagnostic accuracy while dramatically improving convenience, as the enzyme activity can be measured in a single blood spot collected at any time, eliminating the need for multiple draws over hours or days.
Solution Approach 2:
The patent enables the blood spot to serve multiple diagnostic purposes simultaneously. A single blood spot collection provides sufficient sample for comprehensive DPP-IV analysis, including isoform separation and activity measurement, making the testing process self-sufficient and eliminating the need for repeated invasive procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a less invasive, more accurate means of diagnosing and prognosing DPP-associated diseases by effectively measuring and correlating DPP isoform parameters, offering a shift in activity profiles that indicate disease presence and severity, particularly for type 2 diabetes.
Implementation Method 1
measuring parameters of discriminated dipeptidyl peptidase (DPP) isoforms from patient samples using free-flow electrophoresis
Data Source
AI summary
A method is provided for the diagnosis or prognosis of a disease state, involving the measurement of a parameter of discriminated dipeptidyl dipeptidases from a patient sample, and the correlation of the parameter with a disease.